General contact

E-mail Novartis Pharmaceuticals

 

1-888-NOW-NOVA (1-888-669-6682)
Monday - Friday, 8:30am - 5:00pm EST
In case of Medical Emergency, please contact your Physician immediately.

Customer Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
Please allow for mail processing and postal service turnaround time

 

Media

US Pharma Media Relations

Anna Frable, Vice President
Novartis Pharmaceutical Corporation Communications

icon-phone.gif+1 862 778 5388
icon-fax.gif+1 732 673 5262
anna.frable@novartis.com

 

More Information

 

Novartis Patient Assistance
Program

This program is for U.S. Residents only.

1-888-NOW-NOVA
Monday - Friday, 8:30am - 5:00pm EST

Novartis Patient Assistance Program
PO Box 66556
St. Louis, MO 63166-6556



More Information

landing-privacy-img.jpg

Safe Harbor Privacy Statement

Safe Harbor Standards

This Safe Harbor Privacy Statement (the "Statement") sets forth the privacy principles followed by Novartis Pharmaceuticals Corporation (Novartis) in connection with the transfer and protection of "personal information" received from the European Union (EU) or Switzerland.

About The Safe Harbor

The "Safe Harbor" program was jointly established in June 2000 by the United States Department of Commerce and the European Commission, as a method for transferring personal information from the European Union (EU), to companies in the United States. The program is a voluntary self-certification process for companies operating in the United States. Companies that certify represent that they are upholding privacy standards for personal information received from the EU that have been jointly accepted by the EU Commission and the US Department of Commerce. These standards exceed current US privacy standards. Novartis has certified to the Safe Harbor program and makes that commitment.

"Personal Information" means information that can directly or indirectly lead to the identification of a living person, such as an individual's name, address, e-mail, telephone number, license number, medical identification number, photograph, or other identifying characteristic. The identification can occur by reference to one or more factors specific to the individual's physical, physiological, mental, economic, cultural or social identity. Personal information does not include information that has been anonymized, encoded or otherwise stripped of its identifiers, or information that is publicly available, unless combined with other non-public personal information.

Scope

This Statement governs personal information transferred from countries in the EU or Switzerland (which has adopted substantially similar privacy laws to those of the EU), to the United States on behalf of Novartis. It applies to personal information in electronic and off-line formats.

Safe Harbor Privacy Principles

The following privacy principles apply to the transfer, collection, use or disclosure of personal information from the EU by Novartis.

Notice: Novartis informs individuals in the EU about the purposes for which it collects and uses their personal information, how to contact Novartis, the types of third parties with which Novartis shares their personal information, and the choice and means Novartis offers for limiting the use and disclosure of their personal information.

Consistent with the Safe Harbor requirements, Novartis may not be in a position to furnish notice in certain limited situations. Specifically, notice is not required where the processing of EU personal information is necessary to respond to a government inquiry; is required by applicable laws, court orders or government regulations; or is necessary to protect Novartis' legal interests and providing notice would interfere with those interests.

Choice: Novartis will not process personal information about EU individuals for purposes other than those for which the information was originally obtained or subsequently authorized by the EU individual unless the individual affirmatively and explicitly consents ("opt-in") to the processing, or unless an exception applies. Novartis also provides EU individuals with the opportunity to withdraw consent at any time ("opt-out"), in which case their personal information will not be further processed. There are certain limitations on the right to opt-out, such as those that apply in the clinical research situation. In that situation, Novartis can continue to rely upon personal information already provided by clinical research participants who choose to discontinue participation in a clinical trial, to the extent needed to protect the integrity of the study, but cannot collect any additional personal information about that individual once the written request to withdraw participation is received.

Data Integrity: Novartis seeks to ensure that any personal information held about EU individuals is accurate, complete, current and otherwise reliable in relation to the purposes for which the information was obtained. Novartis collects personal information that is adequate, relevant and not excessive for the purposes for which it is to be processed. EU individuals have a responsibility to assist Novartis in maintaining accurate, complete and current personal information about them.

Transfers To Third Parties: Novartis will only transfer personal information about EU individuals to third-parties where the third-party (a) has provided satisfactory assurances to Novartis that it will protect the information consistently with this Statement; or (b) is located in the EU or a country considered "adequate" for privacy by the EU Commission, and therefore is required to comply with the EU data protection laws or substantially equivalent privacy laws; or (c) the third-party has also certified to the Safe Harbor, and is accordingly independently responsible for complying with the Safe Harbor requirements.

Where Novartis has knowledge that a third-party to whom it has provided EU personal information is processing that information in a manner contrary to this Statement or the Safe Harbor requirements, Novartis will take reasonable steps to prevent or stop the processing.

Access And Correction
: Upon written request to Novartis Pharmaceuticals Corporation, Novartis will provide EU individuals with reasonable access to their personal information. Novartis will also take reasonable steps to allow EU individuals to review their information for the purposes of correcting their information. There are certain limitations to the Access and Correction rights, as set forth in the US Department of Commerce's Safe Harbor website.

Security: Novartis takes reasonable precautions to protect EU personal information in its possession from loss, misuse, unauthorized access, disclosure, alteration and destruction.

Enforcement: Novartis has established internal mechanisms to verify its ongoing adherence to this Statement. Novartis also encourages individuals covered by this Statement to raise any concerns about our processing of their personal information by contacting Novartis' Privacy Office at the address below or by contacting their local privacy officer or Legal Department. Novartis will seek to resolve any concerns. Novartis has also agreed to participate in the dispute resolution program provided by the European Data Protection Authorities.

Limitation On Scope Of Principles: Adherence to these Privacy Principles may be limited to the extent required to meet a legal, governmental, national security or public interest obligation.

Contact Information
: Questions or comments about this Statement should be directed to:

Novartis Privacy Office
1 Health Plaza
East Hanover, NJ, USA 07045